Related Experiment Video
Updated: Jun 24, 2026
05:13
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Diverse Methodologies Used for Preclinical Research into Prenatal Cannabis Exposure
Suzy Davies1, Zarena M Dominguez1, Jessie R Maxwell2
1Departments of Pediatrics, University of New Mexico School of Medicine.
Journal of Visualized Experiments : Jove
|June 22, 2026
Summary
Investigating prenatal cannabinoid exposure (PCE) is crucial due to increased cannabis use in pregnancy. This review examines preclinical methods for evaluating THC and CBD safety and efficacy, highlighting challenges and implications for fetal neurodevelopment.
Area of Science:
- Pharmacology
- Neuroscience
- Toxicology
Background:
- Cannabis legalization has increased use among pregnant individuals.
- Cannabis contains compounds like THC and CBD with potential health effects.
- Understanding risks and benefits of prenatal cannabinoid exposure (PCE) is vital for fetal health.
Purpose of the Study:
- To review preclinical research methods for evaluating PCE.
- To identify challenges in assessing cannabis product safety and efficacy.
- To explore implications for evidence-based treatment.
Main Methods:
- In vitro and in vivo preclinical research approaches.
- Utilized methods include cell-based assays, organoid models, and animal models.
- Incorporated artificial intelligence (AI) and machine learning (ML) for analysis.
Main Results:
- Variability in cannabis formulations and administration routes complicates safety and efficacy evaluation.
- Pharmacokinetics and bioavailability differ significantly across products and methods.
- Methodological limitations impact the interpretation of PCE research.
Conclusions:
- Standardized preclinical methods are needed for accurate PCE risk assessment.
- Further research is essential to understand long-term neurodevelopmental effects.
- AI and ML show promise in analyzing complex PCE data.
